Communications Biology (Sep 2023)
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
- Maria Eugénia Marques Da Costa,
- Sakina Zaidi,
- Jean-Yves Scoazec,
- Robin Droit,
- Wan Ching Lim,
- Antonin Marchais,
- Jerome Salmon,
- Sarah Cherkaoui,
- Raphael J. Morscher,
- Anouchka Laurent,
- Sébastien Malinge,
- Thomas Mercher,
- Séverine Tabone-Eglinger,
- Isabelle Goddard,
- Francoise Pflumio,
- Julien Calvo,
- Francoise Redini,
- Natacha Entz-Werlé,
- Aroa Soriano,
- Alberto Villanueva,
- Stefano Cairo,
- Pascal Chastagner,
- Massimo Moro,
- Cormac Owens,
- Michela Casanova,
- Raquel Hladun-Alvaro,
- Pablo Berlanga,
- Estelle Daudigeos-Dubus,
- Philippe Dessen,
- Laurence Zitvogel,
- Ludovic Lacroix,
- Gaelle Pierron,
- Olivier Delattre,
- Gudrun Schleiermacher,
- Didier Surdez,
- Birgit Geoerger
Affiliations
- Maria Eugénia Marques Da Costa
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Sakina Zaidi
- INSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre
- Jean-Yves Scoazec
- Department of Pathology and Laboratory Medicine, Translational Research Laboratory and Biobank, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Robin Droit
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Wan Ching Lim
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Antonin Marchais
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Jerome Salmon
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Sarah Cherkaoui
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Raphael J. Morscher
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Anouchka Laurent
- Gustave Roussy Cancer Campus, INSERM U1170, Université Paris-Saclay, Equipe labellisée Ligue Nationale Contre le Cancer, PEDIAC program
- Sébastien Malinge
- Gustave Roussy Cancer Campus, INSERM U1170, Université Paris-Saclay, Equipe labellisée Ligue Nationale Contre le Cancer, PEDIAC program
- Thomas Mercher
- Gustave Roussy Cancer Campus, INSERM U1170, Université Paris-Saclay, Equipe labellisée Ligue Nationale Contre le Cancer, PEDIAC program
- Séverine Tabone-Eglinger
- Biological Ressources Center, Centre Léon Bérard
- Isabelle Goddard
- Small Animal Platform, Cancer Research Center of Lyon, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, Claude Bernard Université Lyon 1
- Francoise Pflumio
- UMR-E008 Stabilité Génétique, Cellules Souches et Radiations, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Université de Paris-Université Paris-Saclay
- Julien Calvo
- UMR-E008 Stabilité Génétique, Cellules Souches et Radiations, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Université de Paris-Université Paris-Saclay
- Francoise Redini
- INSERM UMR 1238, Université Nantes
- Natacha Entz-Werlé
- Pediatric Onco-Hematology Unit, University Hospital of Strasbourg, Strasbourg, UMR CNRS 7021, team tumoral signaling and therapeutic targets, University of Strasbourg, Faculty of Pharmacy
- Aroa Soriano
- Vall d’Hebron Research Institute (VHIR), Childhood Cancer and Blood Disorders Research Group, Division of Pediatric Hematology and Oncology, Vall d’Hebron Barcelona Hospital Campus
- Alberto Villanueva
- Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat, Xenopat SL, Parc Cientific de Barcelona (PCB)
- Stefano Cairo
- XenTech
- Pascal Chastagner
- Children University Hospital, Vandoeuvre‑lès‑Nancy, University of Nancy
- Massimo Moro
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Cormac Owens
- Paediatric Haematology/Oncology, Children’s Health Ireland
- Michela Casanova
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Raquel Hladun-Alvaro
- Vall d’Hebron Research Institute (VHIR), Childhood Cancer and Blood Disorders Research Group, Division of Pediatric Hematology and Oncology, Vall d’Hebron Barcelona Hospital Campus
- Pablo Berlanga
- Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus
- Estelle Daudigeos-Dubus
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Philippe Dessen
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Ludovic Lacroix
- Department of Pathology and Laboratory Medicine, Translational Research Laboratory and Biobank, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy Cancer Campus, Université Paris-Saclay
- Gaelle Pierron
- Unité de Génétique Somatique, Service d’oncogénétique, Institut Curie
- Olivier Delattre
- INSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre
- Gudrun Schleiermacher
- INSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre
- Didier Surdez
- INSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre
- Birgit Geoerger
- INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay
- DOI
- https://doi.org/10.1038/s42003-023-05320-0
- Journal volume & issue
-
Vol. 6,
no. 1
pp. 1 – 15
Abstract
Abstract Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 131 PDX models were established following heterotopical and/or orthotopical implantation in immunocompromised mice: 76 sarcomas, 25 other solid tumors, 12 central nervous system tumors, 15 acute leukemias, and 3 lymphomas. PDX establishment rate was 43%. Histology, whole exome and RNA sequencing revealed a high concordance with the primary patient’s tumor profile, human leukocyte-antigen characteristics and specific metabolic pathway signatures. A detailed patient molecular characterization, including specific mutations prioritized in the clinical molecular tumor boards are provided. Ninety models were shared with the IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform (IMI2 ITCC-P4) for further exploitation. This PDX biobank of unique recurrent childhood cancers provides an essential support for basic and translational research and treatments development in advanced pediatric malignancies.
